EN DE
Watch Scholar Rock Holding Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Scholar Rock Holding Corp (SRRK) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Scholar Rock Holding Corp stock $27.04, price $48.00, that is 43.7% below the price, quality 36 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

SR Scholar Rock Holding Corp logo Thin data Nov 10, 2026

Scholar Rock Holding Corp

SRRK · US
Very expensive, weak quality

Our calculation puts a fair price 44% below what the stock costs today.

Low debt
Positive coverage
Mixed Growth (revenue 3y +17.4 %/yr in USD)
Insiders bought $12.0M (6M) · sold $923,076
Fair value $27.04 · Strongly overvalued
Quality 36/100
Negative free cash flow
Trails peers (1/7)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Scholar Rock Holding Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$60.04 $4.66 Fair Value $27.04 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $4.66 – $60.04 · fair‑value band $20.28 – $33.80 · the $48.00 price screens above the $27.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Scholar Rock Holding in your weekly email

Every Wednesday you see whether Scholar Rock Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases.

Show moreShow less

The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.

This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors.

The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.

SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies.

The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias.

Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Scholar Rock Holding Corp (SRRK) currently trades at $48.00, while our estimate is $27.04, 44% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $20.28 (bear) to $33.80 (bull), the price of $48.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Scholar Rock Holding Corp reported revenue of $0 in FY2025 versus $18.8M in FY2021. Reported net income was −$378M in FY2025.

Key figures

Market cap $6.3B Mid · EPS (TTM) $−3.32 · Return on equity −168% · Return on assets (EBIT) −56.7% (5-year average) · Free cash flow −$301M · Net cash $215M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 20% below its 52-week high and 63% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −44%, SRRK screens richer than that median.

Fair Value

Bear $20.28 Fair Value $27.04 Bull $33.80
Price $48.00 · Downside -43.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 20
Do the profits arrive as real cash?
Financial strength 93
Debt, balance sheet and risk of trouble
Investment 90
Does it invest with discipline instead of growing at any price?
Low Volatility 44
How calm the share price moves, does not count
Price momentum 54
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 80
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $12.0M, on Oct 26, 2026. Over the same period, 5 people sold shares worth $923,076.

  • BuySrinivas AkkarajuDirector289,470 shares at $41.45$12.0MOct 26, 2026
  • SaleKatie PengDirector2× since Dec 16, 2025: 6,452 shares, avg. $52.35$337,752Jul 1, 202610b5-1 plan
  • SaleJoshua ReedDirector3,053 shares at $53.74$164,075Jul 1, 202610b5-1 plan
  • SaleKristina BurowDirector3,053 shares at $53.74$164,054Jul 1, 202610b5-1 plan
  • SaleMichael GilmanDirector2,544 shares at $53.87$137,057Jul 1, 202610b5-1 plan
  • SaleJeffrey S. FlierDirector3,053 shares at $53.88$164,491Jul 1, 202610b5-1 plan
  • SaleDavid HallalChief Executive Officer, Director2× since Jan 13, 2026: 88,065 shares, avg. $45.09$4.0MApr 16, 2026
  • SaleVikas SinhaChief Financial Officer2× since Jan 13, 2026: 27,165 shares, avg. $45.33$1.2MApr 16, 2026
  • SaleAkshay VaishnawPresident of R&D, Director2× since Jan 13, 2026: 32,684 shares, avg. $45.27$1.5MApr 16, 2026
  • SaleKeith WoodsChief Operating Officer2× since Jan 13, 2026: 26,966 shares, avg. $45.30$1.2MApr 16, 2026

Plus 4 more entries from the last 12 months.

Plus 9 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+76.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+110.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4,277.0% (2016) → −404.8% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SRRK screens overvalued: fair value 44% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (83 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Scholar Rock Holding Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −43.7% · Bottom 25%
Profitability
Return on assets −93.5% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Balance sheet
Debt / equity 0.41× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 25.54× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)80 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs SRRK
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs SRRK
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs SRRK
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs SRRK
argenx SE ARGX $971.55 $908.40 −7% vs SRRK
CSL Limited CSL A$201.68 A$181.40 −10% vs SRRK
Moderna, Inc MRNA $250.83 $158.70 −37% vs SRRK
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs SRRK
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs SRRK
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs SRRK

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Scholar Rock Holding Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Scholar Rock Holding Corp Fair Value". https://www.fairvalue-calculator.com/stock/SRRK

Frequently asked questions

Is Scholar Rock Holding Corp (SRRK) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $27.04 versus a price of $48.00, about 44% lower (overvalued).
What is the fair value of SRRK?
Our estimate for Scholar Rock Holding Corp is $27.04 (as of Nov 10, 2026), built from audited fundamentals. The current price: $48.00.
What is the quality score of SRRK?
Scholar Rock Holding Corp has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Scholar Rock Holding Corp (SRRK)?
Our calculated price target is the estimate of $27.04 (as of Nov 10, 2026). Cautious scenario $20.28, optimistic scenario $33.80. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Scholar Rock Holding Corp stock forecast for 2026?
Our estimate puts fair value at $27.04, about 44% lower versus a price of $48.00 (overvalued). Cautious scenario $20.28, optimistic scenario $33.80. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Scholar Rock Holding Corp (SRRK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Scholar Rock Holding Corp it is $27.04 per share (as of Nov 10, 2026), against a price of $48.00.
Is Scholar Rock Holding Corp stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SRRK trades above its calculated fair value: price $48.00, fair value $27.04, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SRRK?
No. The price is what the market pays today ($48.00); the fair value is what the company's own numbers justify ($27.04). For Scholar Rock Holding Corp the two are $20.96 per share apart. That gap is exactly why we show both numbers side by side.
How much is Scholar Rock Holding Corp worth?
The market values Scholar Rock Holding Corp at about $6.3B (market capitalisation, as of Nov 10, 2026). Per share that is $48.00; our models calculate a fair value of $27.04 per share.
What do the bullish and bearish scenarios say about SRRK?
Our models span a range for Scholar Rock Holding Corp: cautious scenario $20.28, base $27.04, optimistic $33.80 per share (as of Nov 10, 2026, price $48.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Scholar Rock Holding Corp (SRRK)?
Balance-sheet figures for Scholar Rock Holding Corp (as of Nov 10, 2026): return on equity −167.8%, debt of 0.41 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is SRRK from its 52-week high?
Scholar Rock Holding Corp trades at $48.00, about 20% below its 52-week high of $60.04 and 63% above the low of $29.37 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $27.04 is for.
Which stocks are comparable to Scholar Rock Holding Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Scholar Rock Holding Corp stock attractive at the current price?
The data as of Nov 10, 2026: price $48.00, calculated fair value $27.04 (−44%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Scholar Rock Holding Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Scholar Rock Holding Corp (SRRK)?
The closing price on Nov 10, 2026 was $48.00. Our estimate is $27.04, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Scholar Rock Holding Corp right now?
The price sits above even our optimistic bull case ($33.80). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Scholar Rock Holding Corp

How large is the market capitalisation of Scholar Rock Holding Corp (SRRK)?
The market capitalisation of Scholar Rock Holding Corp is $6.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Scholar Rock Holding Corp (SRRK)?
Earnings per share at Scholar Rock Holding Corp are $−3.32. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Scholar Rock Holding Corp (SRRK)?
The return on equity (ROE) of Scholar Rock Holding Corp is −168% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Scholar Rock Holding Corp (SRRK)?
On an EBIT basis the return on assets of Scholar Rock Holding Corp is −56.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Scholar Rock Holding Corp (SRRK) generate?
The free cash flow of Scholar Rock Holding Corp is −$301M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Scholar Rock Holding Corp (SRRK) hold?
Scholar Rock Holding Corp holds more cash than debt, $215M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Scholar Rock Holding Corp in the live analysis

One click puts Scholar Rock Holding Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.